Know HSD.

What HSD is

Hypermobility Spectrum Disorder (HSD) is symptomatic joint hypermobility that doesn't meet the strict 2017 criteria for hypermobile Ehlers-Danlos Syndrome (hEDS). It was formally introduced by the international EDS consortium in the 2017 nomenclature reform to name and validate a large group of patients who had been previously either misdiagnosed with hEDS, misdiagnosed with other conditions, or dismissed entirely.

HSD sits on the same clinical spectrum as hEDS. It is not a milder form of hEDS. It has the same day-to-day symptom picture, the same comorbidity cluster, and the same treatment. Some HSD patients are more disabled than some hEDS patients. The distinction is diagnostic-technical (specific criteria didn't quite hit the strict threshold), not clinical.

HSD is not caused by weakness, deconditioning, or anything the patient did. It reflects underlying differences in connective tissue that are present from birth. The joint hypermobility is structural. Management is about protecting the tissue you have, treating the comorbidities that stack on top, and building a life around the constraint.

The 2017 spectrum reform

Before 2017, the diagnostic landscape was messier. Patients with symptomatic hypermobility were variously called Joint Hypermobility Syndrome (JHS), Ehlers-Danlos Syndrome hypermobility type, or nothing at all. The 2017 international consortium clarified the framework:

• hEDS for patients meeting the strict clinical criteria.
• HSD for patients with symptomatic hypermobility not meeting strict hEDS criteria.
• Asymptomatic hypermobility (just flexible, no symptoms) is not a disease and doesn't need active management.
• The 12 other rarer EDS subtypes each retain their genetic definitions.

The consortium explicitly stated: HSD is not milder than hEDS. Same management. Same clinical space.

The four HSD subtypes

The 2017 consortium defined four HSD subtypes based on the pattern of hypermobility:

• G-HSD (Generalised HSD). Generalised joint hypermobility on Beighton score plus musculoskeletal features, but not meeting the full 2017 hEDS criteria. The most common HSD subtype in clinical practice.
• P-HSD (Peripheral HSD). Hypermobility limited to hands and feet with musculoskeletal features.
• L-HSD (Localised HSD). Hypermobility in a single joint or single body region with musculoskeletal features.
• H-HSD (Historical HSD). Patient no longer meets the Beighton threshold (typically due to age) but historically had generalised hypermobility with current musculoskeletal features.

The subtype classification matters mostly for research; management is largely the same across all four.

HSD vs hEDS

The single most important thing to know about the HSD-vs-hEDS distinction: they are on the same clinical spectrum. Management is identical. Comorbidities cluster the same way. Disability paperwork uses the same processes. The distinction is diagnostic-technical.

Where the distinction can matter:

• Family risk counselling. hEDS is autosomal dominant with 50% risk per child; HSD's genetic pattern is less clear but likely also heritable to some degree.
• Research participation. Some studies specifically enrol hEDS or HSD patients.
• Insurance and disability paperwork. Some systems weight the labels differently even though clinical implications are the same. This is a system flaw, not a clinical reality.

Where it doesn't matter clinically:

• Treatment: same PT approaches, same pain management, same comorbidity treatment.
• Prognosis: same range.
• Day-to-day disability: same picture.

The EDS reference on this site covers the shared clinical picture in more depth. The comorbidity chapter here mirrors that structure so HSD readers don't have to context-switch.

Causes and biology

Like hEDS, HSD is understood as a heritable connective tissue difference. There is no confirmed genetic marker for HSD (or for hEDS). Possibilities being investigated:

• Shared polygenic architecture with hEDS.
• Variants in collagen and related genes not yet fully characterised.
• Overlap with the genetic architecture of adjacent conditions (POTS, MCAS, ADHD, autism).

The connective tissue involvement is real: patients have measurable differences in joint mobility, and often in skin and other tissues. Whether HSD and hEDS are truly separate conditions or one condition with a diagnostic-cutoff artefact is an open scientific question.

Related conditions

The same cluster as EDS: POTS, MCAS, craniocervical instability, tethered cord, gastroparesis, endometriosis, TMJ, dental fragility, and neurodivergence (ADHD, autism, AuDHD). Chapter 6 covers each.

Support for family and loved ones

The specific extra challenge for HSD patients: the diagnostic label itself is often used to dismiss them ("you don't quite have EDS so it's not that bad"). Loved ones can help by understanding the 2017 spectrum framing and by treating the diagnosis with the seriousness it deserves.

What helps: taking cancellations gracefully, learning the early flare signs, being the calm voice during a subluxation, doing physical tasks that involve joints the patient shouldn't stress. What hurts: implying they should just build up strength (they should, but not the way generic gyms suggest), suggesting yoga (the wrong kind can hurt), and dismissing the diagnosis because it isn't the full hEDS label.

The diagnostic no-man's-land

HSD patients often describe their diagnosis experience in a specific way: they finally got a name for what they'd been feeling, but the name comes with an asterisk. "You have HSD, not EDS." "You don't quite meet the criteria." "It's on the spectrum but not the strict form." The 2017 international consortium intended HSD to be a validating diagnosis; in practice, many clinicians and even patients themselves treat it as second-tier.

The lived reality: HSD carries the same symptoms, the same disability picture, and the same comorbidity cluster as hEDS. Patients often spend additional years being dismissed after their HSD diagnosis because "you're not full EDS." The 2017 reform explicitly said this framing is wrong. Clinical culture has been slow to catch up.

Specific gaslighting patterns

HSD patients face all the general hypermobility-related gaslighting (see the EDS reference), plus specific HSD-labelled versions:

• "You have HSD, not EDS, so it's not really that bad."
• "HSD is the milder version." (It isn't; the 2017 consortium said so explicitly.)
• "You didn't quite meet the criteria, so we can't say you have anything really wrong."
• "HSD doesn't need serious treatment; just do some pilates."
• "You're not really disabled, you have HSD not EDS."

The 2017 consortium published clear guidance that HSD is not milder than hEDS. Print out the guidance and bring it to appointments if you need to. The EDS Society has patient-facing versions.

Invisible illness

HSD, like EDS, is largely invisible until it isn't. A patient can look fine sitting in a coffee shop, then dislocate a finger picking up a mug. Over time, subtle signs accumulate (frequent bruising, joints crack constantly, unusual posture, mobility aids appear situationally). For most patients, though, the disease is largely internal.

The invisibility drives specific harms: friends assume they must be exaggerating on bad days, employers assume they should be able to do the same tasks as everyone else, clinicians in single appointments see a person who "looks fine." The extra HSD-specific layer: the diagnostic label itself is used as a reason to disbelieve severity.

Impact on identity

Two overlapping identity threads:

• The general chronic-illness thread: coming to terms with a body that behaves differently than expected, that requires accommodation, that has limits.
• The HSD-specific thread: coming to terms with being "on the spectrum" without the full-EDS label. Many patients describe a specific version of grief for the label they didn't quite get.

The community that best resolves this is the joint hEDS/HSD patient community, which largely treats both diagnoses as one clinical space. The medical world is often less integrated than the patient world.

Isolation

Social isolation in HSD has the same drivers as EDS: cancelled plans, difficulty with some environments, embarrassment about visible symptoms, exhaustion of explaining. Many HSD patients find their most sustaining community online. The Instagram and TikTok hypermobility communities generally include hEDS and HSD together.

Mental health

Anxiety, depression, PTSD, ADHD, and autism are over-represented in HSD the same way they are in EDS. Some of this is consequence (years of dismissal, chronic pain, diagnostic marginalisation) and some is shared underlying biology. Treatment is worthwhile.

Medication choice: SNRIs and low-dose tricyclics are often better-tolerated than SSRIs (which can worsen comorbid POTS in some patients). Low-dose abilify is a growing off-label option for treatment-resistant depression in the HSD / EDS / ME/CFS space.

HSD symptoms are largely the same as hEDS. The presence or absence of specific systemic features (skin, scarring, hernias, etc.) is what determines whether a patient meets hEDS criteria or falls into HSD; the underlying joint-and-tissue picture is the same. This chapter covers the shared symptom picture; for more detail on any subsection, the EDS reference goes deeper.

Joint hypermobility and instability

The signature feature. Joints move beyond normal range because connective tissue is more elastic. Consequences:

• Subluxations. Partial dislocations of shoulders, fingers, hips, knees, ribs, TMJ.
• Dislocations. Full dislocations, sometimes multiple per year in moderate-to-severe patients.
• Chronic joint pain. From surrounding tissue overworking to stabilise loose joints.
• Injury with minimal trauma. Sprains and ligament tears from ordinary movement.
• Postural changes. Compensatory postures develop over years.
• Early joint wear. Cumulative damage can produce early arthritis in a subset.

The Beighton score measures generalised hypermobility (0-9); it's the entry criterion for HSD, but doesn't correlate directly with disability. Joint instability, subluxation frequency, and functional impact matter more clinically than the Beighton number.

Pain

Chronic pain is one of the biggest quality-of-life issues in HSD, same as in hEDS. Drivers include mechanical joint pain, muscle pain from constant stabilising, nerve pain (small fibre neuropathy in a subset), nociplastic pain overlap with fibromyalgia, headaches and migraines, abdominal pain from GI dysmotility, pelvic pain from pelvic-floor dysfunction and endometriosis, and central sensitisation.

Pain management is layered: PT foundation, local approaches (heat, ice, TENS, topical NSAIDs, lidocaine patches), oral medications (paracetamol first, cautious NSAIDs, SNRIs like duloxetine, low-dose amitriptyline, gabapentinoids), and coordinated pain-clinic involvement for severe cases. Long-term opioids are generally discouraged. See the EDS pain management section for the layered approach.

Autonomic dysfunction and POTS

Autonomic symptoms are near-universal in HSD, just as in hEDS. Most patients meet POTS criteria on a properly-done stand test:

• Standing heart rate spikes.
• Lightheadedness, presyncope, occasional fainting.
• Brain fog on standing.
• Heat intolerance.
• Post-meal crashes.
• Temperature regulation problems.
• Chronic fatigue that tracks with orthostatic load.

Treating the POTS often produces the biggest single functional improvement. Foundations: 2-3L fluid, 8-10g sodium, waist-high compression. Medications: beta blockers or ivabradine, midodrine, fludrocortisone, pyridostigmine. The POTS reference covers the full picture.

GI dysmotility

Connective tissue is throughout the gut wall. GI symptoms in HSD mirror those in hEDS:

• Gastroparesis (delayed stomach emptying).
• Slow-transit constipation.
• Rectal prolapse, particularly with straining.
• IBS-pattern symptoms.
• Gastroesophageal reflux.
• SIBO (small intestinal bacterial overgrowth).
• Nausea, early satiety, post-meal crashes.

Workup: gastric emptying study, colonoscopy, upper endoscopy where indicated. Treatment: smaller more frequent meals, prokinetics where indicated, pelvic-floor PT, dietary work with a hypermobility-aware dietitian.

Dental and TMJ

TMJ dysfunction is common: subluxations, clicking, jaw pain, headaches from muscle tension. Dental fragility (gum recession, tooth wear, sensitivity, occasional local-anaesthetic issues) also over-represented. Find an EDS-aware dentist where possible. Custom mouthguards for TMJ and grinding.

Gynaecological

Same picture as hEDS. Heavy or painful periods, endometriosis (heavily over-represented), adenomyosis, pelvic-floor dysfunction, uterine or bladder prolapse (particularly postpartum), cyclical symptom flares tied to the hormone cycle, complicated pregnancies. Any menstruating HSD patient with severe pelvic pain deserves an endometriosis workup.

Fatigue

Chronic, disproportionate fatigue is common in HSD. Drivers include the metabolic cost of stabilising loose joints, autonomic dysfunction (POTS overlap), poor sleep, anaemia (over-represented), central sensitisation, nutritional deficiencies with GI involvement, and ME/CFS overlap in a subset.

The Beighton score

The Beighton score is a 9-point scale for generalised joint hypermobility. Age-adjusted thresholds:

• Pre-pubertal children: 6/9 or higher
• Pubertal men and women up to age 50: 5/9 or higher
• Adults over 50: 4/9 or higher

A patient meeting the Beighton threshold with musculoskeletal features but not meeting the full 2017 hEDS criteria will typically receive a diagnosis of HSD. Note that hypermobility naturally decreases with age; a patient who scored 7 at 20 may score 4 at 50. The historical HSD subtype (H-HSD) accounts for this. See the EDS Beighton section for the full scoring detail.

HSD diagnostic criteria

HSD is a diagnosis of exclusion within the hypermobility spectrum. In practice:

1. Patient has generalised joint hypermobility (Beighton score at threshold) or the historical version.
2. Patient has musculoskeletal symptoms attributable to hypermobility (chronic pain, subluxations, joint instability).
3. Patient does NOT meet the full 2017 hEDS criteria (fewer than 5 of 12 systemic features, or no positive family history, or no musculoskeletal complications, etc.).
4. Other hypermobility-related conditions have been ruled out (Marfan, Loeys-Dietz, other EDS subtypes, autoimmune disease).

Subtypes:

• G-HSD (Generalised). Meets Beighton criteria plus musculoskeletal symptoms. Most common in clinical practice.
• P-HSD (Peripheral). Hypermobility limited to hands and feet with musculoskeletal features.
• L-HSD (Localised). Single joint or single region hypermobility with symptoms.
• H-HSD (Historical). No longer meets Beighton threshold (typically due to age) but previously did, with current symptoms.

Differential diagnosis

Before finalising HSD, consider:

• hEDS. Re-check the 2017 criteria carefully; some HSD patients could meet hEDS with a more thorough systemic review.
• Other EDS subtypes. Particularly vEDS if any red flags (see the EDS vEDS section).
• Marfan syndrome, Loeys-Dietz, other heritable connective tissue disorders.
• Autoimmune rheumatologic disease. Sjögren's, lupus, RA (which can produce joint symptoms with normal or increased mobility).
• Simple asymptomatic hypermobility. If there are no symptoms, HSD isn't the right label; asymptomatic hypermobility is not a disease.

Physiotherapy

Hypermobility-literate physiotherapy is the single highest-leverage intervention. Same principles as hEDS:

• Strength before stretch.
• Small ranges, high frequency.
• Joint-neutral position.
• Proprioception training.
• Progressive loading.
• Consistency over intensity (20 minutes most days beats 90 minutes twice a week).

Community-endorsed approaches: the Muldowney Protocol, Jeannie Di Bon's Integral Movement Method, and Chimera Health content are all applicable to HSD. Certified EDS-aware physiotherapists (via the Ehlers-Danlos Society directory) work with HSD patients the same way they work with hEDS patients. See the EDS physiotherapy section for the full detail.

Pain management

Layered approach, same as hEDS: PT foundation, local approaches (heat, ice, TENS, topical NSAIDs, lidocaine patches, kinesiology tape), oral non-opioids (paracetamol, cautious NSAID use), neuromodulators (amitriptyline, duloxetine, gabapentinoids), and coordinated pain-clinic involvement for severe cases. Long-term opioids generally discouraged. See the EDS pain management section for the full ladder.

Treat the comorbidities

Most functional gain in HSD comes from treating the comorbidities in parallel. Priority screens:

• POTS. Stand test in every HSD patient; roughly half meet criteria. Treatment often lifts a functional level.
• MCAS. Screen for flushing, food reactions, drug sensitivities. Trial H1/H2 antihistamines.
• Sleep apnea. A sleep study is worth it.
• Iron deficiency, B12, thyroid. Ferritin under 75 is functional.
• Endometriosis. Consider in any menstruating patient with pelvic pain.
• GI dysmotility. Gastric emptying study if symptoms suggest.
• ADHD, autism. Neuropsychiatric assessment for late-recognised traits.

What helps versus what harms

Experimental and emerging

• hEDS gene search. Same landscape as EDS; if a hEDS gene is found, HSD categorisation may shift.
• Prolotherapy and PRP. Same caveats as EDS; weak evidence.
• Emerging autonomic and MCAS treatments. Ivabradine, mestinon, low-dose naltrexone all used off-label.
• CCI and tethered cord surgery. Same landscape; multidisciplinary opinion essential.

Tools, apps, and the kit patients actually use

Tracking and monitoring

• Rox. Tracks joint incidents, PT consistency, pain patterns, and the POTS / MCAS / GI comorbidities that stack on top. Turns months of data into a coordinated-care picture. App Store.
• Wearable HR / HRV for the POTS-overlap subset.
• Symptom diaries. Simple tracking of joint incidents, pain, PT adherence, sleep, cycle for menstruating patients.

Joint protection

• Compression garments (waist-high for POTS; joint-specific for hypermobile joints).
• Silver ring splints or Oval-8 finger splints.
• Kinesiology tape for proprioceptive feedback.
• Ergonomic setup (split keyboard, vertical mouse, monitor arm, sit-stand desk, footrest, saddle chair).
• Supportive footwear and custom orthotics for some patients.
• Mobility aids for high-cost days (rollator, folding cane-seat, wheelchair for travel).

Home setup

• Shower stool (IKEA BÄSINGEN is the community favourite).
• Grabber tools, sock aids, button hooks, ergonomic kitchen tools.
• Firm supportive mattress and pillow setup.

Finding the right clinician

• Ehlers-Danlos Society clinician directory (covers HSD as well as EDS).
• Ehlers-Danlos Support UK.
• Specialist hypermobility clinics at major academic centres.
• Hypermobility-certified physiotherapists.
• EDS-aware dentists (harder to find; the community can help).

Prognosis

HSD prognosis mirrors hEDS: not life-shortening, with a highly variable disability picture. Most patients find a workable baseline with consistent PT, joint protection, and comorbidity treatment. Many describe meaningful improvement over years once the right pieces are in place. The gap between well-managed and unmanaged HSD is large.

Pacing and joint protection

Same daily engineering as hEDS: pacing, joint neutral positions, load management, prophylactic bracing, resting joints proactively, adaptive tools, environmental design, appropriate sleep setup. See the EDS pacing and joint protection section for the full list. All of it applies to HSD.

Work and disability

The work picture depends on severity:

• Mild HSD: often compatible with most desk-based work with ergonomic setup.
• Moderate HSD: often needs part-time, remote, or accommodated work.
• Severe HSD: full-time work is often unsustainable.

Accommodations are the same as for hEDS: ergonomic equipment, flexibility around appointments, permission to use mobility aids, remote-work options during flares.

Disability paperwork: HSD counts under disability legislation in most jurisdictions when symptoms substantially impair daily life. The 2017 international consortium's explicit statement that HSD is not milder than hEDS is worth citing on paperwork if the label matters administratively. Start documenting during a flare; it's harder later.

Fertility and pregnancy

Same considerations as hEDS. Fertility generally normal. Pregnancy carries increased risks (preterm labour, pelvic-girdle pain, joint laxity worsening, postpartum joint instability, pelvic-floor damage). Pre-conception planning with an obstetrician familiar with hypermobility helps. HSD inheritance patterns are less clear-cut than most EDS subtypes, but there's likely a hereditary component.

Adapting life around the illness

The arc most HSD patients describe is the same as EDS: years of pushing through and getting hurt, hitting a wall, accepting the disease as a constraint, then designing a meaningful life inside it. Practical engineering that helps:

• Environment designed around the illness: ergonomic everything, bedside-everything, no high shelves you use daily.
• Consistent PT built into daily routine.
• Cyclic tracking for menstruating patients.
• Pre-emptive rest before high-load events; recovery days after.
• Community with other hypermobility patients (hEDS + HSD spaces overlap significantly).
• One or two people who will keep believing the illness on good days.
• Regular check-ins on comorbidities (POTS, MCAS, GI, mental health).

HSD carries the same comorbidity cluster as hEDS. Treating each condition separately, in parallel with the HSD itself, is what usually moves a patient's functional level. The EDS comorbidities chapter covers the shared picture in more depth; this chapter names each condition and cross-references for detail.

The trifecta

HSD, POTS, and MCAS co-occur so often that clinicians treat them as one triad. Roughly half of HSD patients meet POTS criteria on a properly-done stand test; a substantial minority meet MCAS criteria. Screening for all three should be standard care.

POTS

Postural Orthostatic Tachycardia Syndrome. Standing heart-rate spikes, lightheadedness, brain fog on standing, heat intolerance, post-meal crashes. Foundations: fluids, sodium, compression. Medications: beta blockers or ivabradine, midodrine, fludrocortisone, pyridostigmine. See the POTS reference for the full picture.

MCAS

Mast Cell Activation Syndrome. Flushing, hives, food and drug reactions, GI symptoms, unexplained sensitivities. Diagnosis largely clinical. Treatment: H1 antihistamines, H2 antihistamines, mast-cell stabilisers, low-histamine diet for the responsive subset.

GI and gastroparesis

Slow gastric emptying, IBS-pattern symptoms, reflux, SIBO, pelvic-floor dysfunction. Gastric emptying study when symptoms suggest. Treatment: smaller more frequent meals, prokinetics where indicated, pelvic-floor PT, dietary work with a hypermobility-aware dietitian.

Endometriosis

Heavily over-represented in HSD (and EDS) patients with uteruses. Chronic pelvic pain, heavy or painful periods, cyclical GI symptoms, pain with intercourse. Diagnosis via laparoscopy; treatment can include hormonal management, excision surgery by an endometriosis specialist, and pain management.

TMJ and dental

TMJ dysfunction, jaw pain, clicking, subluxation, headaches from muscle tension. Custom mouthguard, TMJ-specific physio, occasionally injections. Dental fragility (gum recession, tooth wear, potential local-anaesthetic difficulty) benefits from an EDS-aware dentist. See the EDS TMJ and dental section.

ADHD, autism, AuDHD

ADHD and autism are heavily over-represented in the HSD community, often diagnosed late. The mechanisms probably include shared genetic architecture, connective-tissue involvement in the nervous system, and central sensitisation. Late recognition matters; treatment often changes life quality significantly.

The current scientific picture

HSD is the same clinical space as hEDS. The research picture is the same:

• The hEDS/HSD gene search continues; no confirmed marker yet. Possibly polygenic.
• The trifecta (hypermobility + POTS + MCAS) is increasingly formally recognised.
• Long COVID has driven attention to post-viral dysautonomia and MCAS, which benefits the HSD research space as well.
• The 2017 international nomenclature reform is still the operating framework and worth being familiar with.

The EDS current-picture section covers the mechanistic landscape in more depth; HSD sits on the same spectrum.

Active research directions

• hEDS/HSD gene identification. Multiple groups; the HEDGE study is the largest.
• Autonomic dysfunction biology. The POTS overlap has driven research into shared mechanisms.
• Small fibre neuropathy prevalence. Documented in a subset; more work ongoing.
• MCAS diagnostic criteria and prevalence.
• PT trials. Comparative trials of different hypermobility PT approaches.
• Endometriosis-hypermobility link.
• Neurodivergence prevalence. ADHD/autism prevalence and shared architecture with hypermobility.

Key sources worth knowing

• The Ehlers-Danlos Society. Explicitly covers HSD alongside EDS. The clinical framework, patient resources, and clinician directory all include HSD.
• Ehlers-Danlos Support UK. Covers HSD.
• The 2017 international classification papers in the American Journal of Medical Genetics. The document that formalised HSD as a diagnostic category.
• Kevin Muldowney's book and the Muldowney Protocol for PT.
• Jeannie Di Bon's Integral Movement Method.
• The Ehlers-Danlos Society YouTube channel.
• The Bendy Bodies Podcast.

Content creators worth knowing

The hEDS and HSD creator ecosystems are essentially one space, since clinicians and patient creators treat the two diagnoses interchangeably in practice. The EDS creators section is the same list. Highlights:

Resources and community

• r/ehlersdanlos on Reddit. Includes HSD in scope.
• Facebook hypermobility groups. Country- and topic-specific.
• Ehlers-Danlos Society local chapters and annual conferences. Explicitly cover HSD.
• The Zebra Network and other patient-led support communities.

Where to start if you've just been diagnosed

1. Rule out other EDS subtypes if any red flags (particularly vEDS).
2. Find a hypermobility-literate physiotherapist. Start with 20 minutes most days.
3. Get a stand test for POTS; treat it if present.
4. Screen for MCAS, sleep apnea, iron deficiency, thyroid, endometriosis.
5. Get an EDS-aware dentist.
6. Build a joint-protection plan and pain-management plan.
7. Start disability paperwork during a flare.
8. Find one supportive community (hEDS + HSD spaces are largely one community).
9. Read the 2017 international criteria so you understand the framework.
10. Insist on the 2017 consortium's explicit statement that HSD is not milder than hEDS whenever a clinician tries to dismiss the diagnosis.

About this reference

This is a living document. It will be updated as new research emerges and as community-sourced Reddit research becomes available. The medical claims here are drawn from the 2017 international classification, the Ehlers-Danlos Society clinical resources, and published hypermobility literature. None of this is personal medical advice. For your situation specifically, talk with a hypermobility-literate clinician.